{"nctId":"NCT01682759","briefTitle":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","startDateStruct":{"date":"2012-09-10","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":751,"armGroups":[{"label":"Omarigliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin","Drug: Glimepiride Placebo","Drug: Metformin","Drug: Insulin Glargine"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo to Omarigliptin","Drug: Glimepiride","Drug: Metformin","Drug: Insulin Glargine"]}],"interventions":[{"name":"Omarigliptin","otherNames":[]},{"name":"Placebo to Omarigliptin","otherNames":[]},{"name":"Glimepiride","otherNames":["AMARYL®","GLIMY"]},{"name":"Glimepiride Placebo","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Insulin Glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes mellitus\n* On a stable dose of metformin (≥1500 mg/day) for at least 12 weeks with inadequate glycemic control\n* Females of reproductive potential agree to remain abstinent or use or have their partner use acceptable methods of birth control\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* Treated with any antihyperglycemic agents (AHA) therapies other than the protocol-required metformin within the prior 12 weeks of study participation or with omarigliptin at any time prior to signing informed consent\n* On a weight loss program and is not in the maintenance phase or has\n\nstarted a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation\n\n* Medical history of active liver disease (other than non-alcoholic\n\nhepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n\n* Human immunodeficiency virus\n* New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke or transient ischemic neurological disorder within the past 3 months\n* History of malignancy ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer, or in situ\n\ncervical cancer\n\n* Clinically important hematological disorder (such as aplastic anemia,\n\nmyeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n* Pregnant or breast-feeding, or is expecting to conceive or donate eggs\n\nduring the trial, including 21 days following the last dose of study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C at Week 54","description":"Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":null},{"groupId":"OG001","value":"-0.48","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"61.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 54","description":"Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54","description":"The percentage of participants who achieved A1C values \\<6.5% (48 mmol/mol) in the FAS Population at Week 54.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue","description":"Symptomatic episode of hypoglycemia was an episode with clinical symptoms reported by the investigator as hypoglycemia (concurrent fingerstick glucose not required).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54","description":"The percentage of participants who achieved A1C values \\<7.0% (53 mmol/mol) in the FAS Population at Week 54.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"58.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":375},"commonTop":["Hypoglycaemia","Nasopharyngitis"]}}}